caa a22 4500 445887982 CHVBK 20180317145605.0 cr unu---uuuuu 170323e20110901xx s 000 0 eng 10.1007/s00535-011-0414-x doi (NATIONALLICENCE)springer-10.1007/s00535-011-0414-x Serodiagnosis of Helicobacter hepaticus infection in patients with liver and gastrointestinal diseases: western blot analysis and ELISA using a highly specific monoclonal antibody for H. hepaticus antigen [Elektronische Daten] [Kazunari Murakami, Ryoki Takahashi, Masami Ono, Koichiro Watanabe, Tadayoshi Okimoto, Masaaki Kodama, Daijiro Abe, Moto Kimura, Toshio Fujioka] Background: Helicobacter hepaticus infection might be associated with liver and biliary tract diseases. To investigate its pathogenic role, the properties of anti-H. hepaticus serum antibody in patients with liver and diseases were elucidated. Methods: Serum samples were collected from 166 patients-69 with liver diseases, 38 with upper gastrointestinal diseases, 17 with lower gastrointestinal diseases, 26 with biliary tract diseases, and 16 with pancreas diseases; 30 control sera were obtained from 30 healthy blood donors. Serum samples were analyzed by enzyme-linked immunosorbent assay (ELISA) and western blot using the new monoclonal antibody HR II-51. Results: Anti-H. hepaticus serum antibody concentrations in patients with liver disease (n=69) were significantly increased compared with those in other disease groups (p=0.014 to <0.001). Particularly, liver cirrhosis (n=19) showed a significantly higher antibody level compared with other liver diseases (n=50, p=0.005) and healthy donors (n=30, p=0.0005), as well as a higher seroprevalence (68.4%) compared with other liver diseases (p=0.05) and healthy donors (p=0.004). Furthermore, the ELISA value in liver cirrhosis (n=19) was significantly higher than that in patients with hepatitis B virus (HBV)—and/or hepatitis C virus (HCV)-infected chronic hepatitis (n=15) (0.389±0.084 vs. 0.350±0.084, p=0.029). However, there was no relationship between the total immunoglobulin concentration and the anti-H. hepaticus antibody level in each liver disease (Spearman's rank correlation coefficient [rs]<0.225). Conclusions: H. hepaticus infection might play a role in the development of liver diseases; in particular, it might increase the risk of the development of HBV- and/or HCV-infected liver diseases. Springer, 2011 Helicobacter hepaticus nationallicence Serodiagnosis nationallicence Liver diseases nationallicence Gastrointestinal disease nationallicence ELISA nationallicence Murakami Kazunari Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, 879-5593, Yuhu, Oita, Japan aut Takahashi Ryoki Wakamoto Pharmaceutical Co., Ltd., Sagami Research Laboratories, Ashigarakami-gun, Kanagawa, Japan aut Ono Masami Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, 879-5593, Yuhu, Oita, Japan aut Watanabe Koichiro Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, 879-5593, Yuhu, Oita, Japan aut Okimoto Tadayoshi Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, 879-5593, Yuhu, Oita, Japan aut Kodama Masaaki Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, 879-5593, Yuhu, Oita, Japan aut Abe Daijiro Wakamoto Pharmaceutical Co., Ltd., Sagami Research Laboratories, Ashigarakami-gun, Kanagawa, Japan aut Kimura Moto Wakamoto Pharmaceutical Co., Ltd., Sagami Research Laboratories, Ashigarakami-gun, Kanagawa, Japan aut Fujioka Toshio Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, 879-5593, Yuhu, Oita, Japan aut Journal of Gastroenterology Springer Japan 46/9(2011-09-01), 1120-1126 0944-1174 46:9<1120 2011 46 535 https://doi.org/10.1007/s00535-011-0414-x text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00535-011-0414-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Murakami Kazunari Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, 879-5593, Yuhu, Oita, Japan aut NATIONALLICENCE 700 1- Takahashi Ryoki Wakamoto Pharmaceutical Co., Ltd., Sagami Research Laboratories, Ashigarakami-gun, Kanagawa, Japan aut NATIONALLICENCE 700 1- Ono Masami Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, 879-5593, Yuhu, Oita, Japan aut NATIONALLICENCE 700 1- Watanabe Koichiro Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, 879-5593, Yuhu, Oita, Japan aut NATIONALLICENCE 700 1- Okimoto Tadayoshi Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, 879-5593, Yuhu, Oita, Japan aut NATIONALLICENCE 700 1- Kodama Masaaki Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, 879-5593, Yuhu, Oita, Japan aut NATIONALLICENCE 700 1- Abe Daijiro Wakamoto Pharmaceutical Co., Ltd., Sagami Research Laboratories, Ashigarakami-gun, Kanagawa, Japan aut NATIONALLICENCE 700 1- Kimura Moto Wakamoto Pharmaceutical Co., Ltd., Sagami Research Laboratories, Ashigarakami-gun, Kanagawa, Japan aut NATIONALLICENCE 700 1- Fujioka Toshio Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, 879-5593, Yuhu, Oita, Japan aut NATIONALLICENCE 773 0- Journal of Gastroenterology Springer Japan 46/9(2011-09-01), 1120-1126 0944-1174 46:9<1120 2011 46 535 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer